Murray Stahl’s Galectin Therapeutics GALT Stock Holding History

Murray Stahl’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$218K	Sell	46,968 -2,258	-5%	-$5.85K	﹤0.01%	292
2026 Q1	$137K	Sell	49,226 -2,258	-4%	-$6.87K	﹤0.01%	316
2025 Q4	$214K	Sell	51,484 -2,258	-4%	-$11.9K	﹤0.01%	290
2025 Q3	$228K	Buy	53,742 +2,258	+4%	+$8.49K	﹤0.01%	291
2025 Q2	$109K	Sell	51,484 -2,258	-4%	-$3.38K	﹤0.01%	333
2025 Q1	$65.6K	Hold	53,742	–	–	﹤0.01%	333
2024 Q4	$69.3K	Buy	53,742 +2,258	+4%	+$5.41K	﹤0.01%	335
2024 Q3	$142K	Sell	51,484 -2,258	-4%	-$5.54K	﹤0.01%	319
2024 Q2	$121K	Hold	53,742	–	–	﹤0.01%	305
2024 Q1	$128K	Hold	53,742	–	–	﹤0.01%	298
2023 Q4	$89.2K	Sell	53,742 -2,258	-4%	-$4.38K	﹤0.01%	312
2023 Q3	$108K	Hold	56,000	–	–	﹤0.01%	309
2023 Q2	$80.6K	Hold	56,000	–	–	﹤0.01%	321
2023 Q1	$118K	Buy	56,000 +30,000	+115%	+$48.4K	﹤0.01%	312
2022 Q4	$29.4K	Hold	26,000	–	–	﹤0.01%	314
2022 Q3	$42K	Hold	26,000	–	–	﹤0.01%	321
2022 Q2	$34K	Hold	26,000	–	–	﹤0.01%	331
2022 Q1	$42K	Buy	26,000 +2,000	+8%	+$3.87K	﹤0.01%	342
2021 Q4	$50K	Hold	24,000	–	–	﹤0.01%	345
2021 Q3	$93K	Hold	24,000	–	–	﹤0.01%	332
2021 Q2	$77K	Buy	+24,000	New	+$85.4K	﹤0.01%	341

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Murray Stahl's GALT Position: Q2 2026 in Review

Murray Stahl reduced its Galectin Therapeutics (GALT) stake by 4.6% in Q2 2026, selling an estimated $5.85K and leaving 46,968 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #292.

Murray Stahl first reported a position in GALT in Q2 2021 and has held it in 21 quarters since. The position peaked at $228K in Q3 2025. 97 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Murray Stahl held 46,968 shares of Galectin Therapeutics worth $218K as of Q2 2026.
Murray Stahl sold 2,258 Galectin Therapeutics shares in Q2 2026, an estimated $5.85K.
Galectin Therapeutics made up ﹤0.01% of Murray Stahl's portfolio in Q2 2026, its #292 holding.
Murray Stahl first reported a position in Galectin Therapeutics in Q2 2021 and has held it in 21 quarters since.
Murray Stahl's Galectin Therapeutics position peaked at $228K in Q3 2025.
97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.